학술논문
전자자료 공정이용 안내
우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.
공정이용 지침
- 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
- 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
- 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
- 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
- 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
- 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
- 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
- 상업적·영리적 목적으로 자료를 전송·복제·활용
- ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
- EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
- 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
- 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
- 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문'
에서 검색결과 78건 | 목록
1~20
Academic Journal
Ahmad, Mohammad; Thorel, L.; Brotin, E.; Abeilard, E.; N'Diaye, M.; Sebda, Shéhérazade; Meneboo, Jean-Pascal; Figeac, Martin; Bernay, B.; Poulain, L.; Weiswald, L. B.; Denoyelle, C.; Meryet-Figuière, Matthieu
Noncoding RNA Res
Academic Journal
Evenden, P; Vandoolaeghe, Q; Lecluse, Y; Gac, A; Delépée, R; Weiswald, L; Boutet-Robinet, E; Boutet-Robinet, Elisa; Boulanger, M; Bonassi, S; Lebailly, P; Meryet-Figuière, M
Int Arch Occup Environ Health
Academic Journal
L. Thorel; E. Dolivet; P-M. Morice; R. Florent; J. Divoux; M. Perréard; L. Lecouflet; G. Desmartin; C. Marde Alagama; F. Giffard; A. Leconte; J. Lequesne; B. Clarisse; M. Briand; A. Traore; C. Villenet; JP. Meneboo; G. Babin; L. Gaichies; S. Martin-Françoise; JF. Le Brun; R. Rouzier; E. Brotin; C. Denoyelle; N. Vigneron; R. Leman; D. Vaur; L. Castera; C. Blanc-Fournier; N. Elie; B. Plancoulaine; F. Joly; M. Meryet-Figuière; M. Figeac; L-B. Weiswald; L. Poulain
J Exp Clin Cancer Res
Academic Journal
Thorel, L.; Divoux, J.; Lequesne, J.; Babin, G.; Morice, P. M.; Florent, R.; Desmartin, G.; Lecouflet, L.; Marde Alagama, C.; Leconte, A.; Clarisse, B.; Briand, M.; Rouzier, R.; Gaichies, L.; Martin-Françoise, S.; Le Brun, J. F.; Denoyelle, C.; Vigneron, N.; Jeanne, C.; Blanc-Fournier, C.; Leman, R.; Vaur, D.; Figeac, Martin; Meryet-Figuière, Matthieu; Joly, F.; Weiswald, L. B.; Poulain, L.; Dolivet, E.
BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Academic Journal
Dabakuyo-Yonli, S. ; Bara, S. ; Bouvier, A.M. ; Busquet, T. ; Colonna, M. ; Coureau, G. ; Delanoé, M. ; Grosclaude, P. ; Guizard, A.V. ; Herbrecht, P. ; Laplante, J.J. ; Lapotre-Ledoux, B. ; Launoy, G. ; Lenoir, D. ; Hammas, K. ; Marcotullio, E. ; Maynadié, M. ; Molinié, F. ; Monnereau, A. ; Paumier, A. ; Jarriges, J. ; Thibaudier, J.M. ; Troussard, X. ; Velten, M. ; Wavelet, E. ; Woronoff, A.S. ; Talibov, Madar ; Tual, Séverine ; Morlais, Fabrice ; Meryet-Figuière, Matthieu ; Boulanger, Mathilde ; Bouvier, Véronique ; Perrier, Stephanie ; Clin, Bénédicte ; Baldi, Isabelle ; Lebailly, Pierre
In Cancer Epidemiology June 2022 78
Academic Journal
de Graaf, L. ; Boulanger, M. ; Bureau, M. ; Bouvier, G. ; Meryet-Figuiere, M. ; Tual, S. ; Lebailly, P. ; Baldi, I.
In Environmental Research January 2022 203
Academic Journal
Thorel L; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Dolivet E; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Department of Surgery, Caen, France.; Morice PM; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; Florent R; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Université de Caen Normandie, PLATON Services Unit, ORGAPRED Core Facility, Caen, France.; Divoux J; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Université de Caen Normandie, PLATON Services Unit, ORGAPRED Core Facility, Caen, France.; Perréard M; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; Lecouflet L; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Université de Caen Normandie, PLATON Services Unit, ORGAPRED Core Facility, Caen, France.; Desmartin G; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Université de Caen Normandie, PLATON Services Unit, ORGAPRED Core Facility, Caen, France.; Alagama CM; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Giffard F; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Université de Caen Normandie, PLATON Services Unit, VIRTUAL'HIS Core Facility, Caen, France.; Leconte A; UNICANCER, Comprehensive Cancer Center François Baclesse, Clinical Research Department, Caen, France.; Lequesne J; UNICANCER, Comprehensive Cancer Center François Baclesse, Clinical Research Department, Caen, France.; Clarisse B; UNICANCER, Comprehensive Cancer Center François Baclesse, Clinical Research Department, Caen, France.; Briand M; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Université de Caen Normandie, PLATON Services Unit, Biological Resource Center 'OvaRessources', Caen, France.; Traoré A; University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.; Villenet C; University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.; Meneboo JP; University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.; Babin G; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Department of Surgery, Caen, France.; Gaichies L; UNICANCER, Comprehensive Cancer Center François Baclesse, Department of Surgery, Caen, France.; Martin-Françoise S; UNICANCER, Comprehensive Cancer Center François Baclesse, Department of Surgery, Caen, France.; Brun JL; UNICANCER, Comprehensive Cancer Center François Baclesse, Department of Surgery, Caen, France.; Rouzier R; UNICANCER, Comprehensive Cancer Center François Baclesse, Department of Surgery, Caen, France.; Brotin E; Université de Caen Normandie, PLATON Services Unit, ImpedanCELL Core Facility, Caen, France.; Denoyelle C; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Université de Caen Normandie, PLATON Services Unit, ImpedanCELL Core Facility, Caen, France.; Vigneron N; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Calvados General Tumor Registry, Caen, France.; Leman R; UNICANCER, Comprehensive Cancer Center François Baclesse, Laboratory of Biology and Cancer Genetics, Caen, France.; Normandie Université, INSERM U1245, Cancer Brain and Genomics, FHU G4 Génomique, Rouen, France.; Vaur D; UNICANCER, Comprehensive Cancer Center François Baclesse, Laboratory of Biology and Cancer Genetics, Caen, France.; Normandie Université, INSERM U1245, Cancer Brain and Genomics, FHU G4 Génomique, Rouen, France.; Castera L; UNICANCER, Comprehensive Cancer Center François Baclesse, Laboratory of Biology and Cancer Genetics, Caen, France.; Normandie Université, INSERM U1245, Cancer Brain and Genomics, FHU G4 Génomique, Rouen, France.; Blanc-Fournier C; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; Université de Caen Normandie, PLATON Services Unit, Biological Resource Center 'OvaRessources', Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Department of Bio-Pathology, Caen, France.; Elie N; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; Université de Caen Normandie, PLATON Services Unit, VIRTUAL'HIS Core Facility, Caen, France.; Plancoulaine B; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Vilnius University, Institute of Biomedical Sciences, Faculty of Medicine, Forensic Medicine and Pharmacology, Department of Pathology, Vilnius, Lithuania.; Joly F; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Clinical Research Department, Caen, France.; Meryet-Figuière M; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France.; Figeac M; University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.; Weiswald LB; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France. lb.weiswald@baclesse.unicancer.fr.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France. lb.weiswald@baclesse.unicancer.fr.; Université de Caen Normandie, PLATON Services Unit, ORGAPRED Core Facility, Caen, France. lb.weiswald@baclesse.unicancer.fr.; Poulain L; Université de Caen Normandie, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Caen, France. l.poulain@baclesse.unicancer.fr.; UNICANCER, Comprehensive Cancer Center François Baclesse, Caen, France. l.poulain@baclesse.unicancer.fr.; Université de Caen Normandie, PLATON Services Unit, ORGAPRED Core Facility, Caen, France. l.poulain@baclesse.unicancer.fr.; Université de Caen Normandie, PLATON Services Unit, Biological Resource Center 'OvaRessources', Caen, France. l.poulain@baclesse.unicancer.fr.
Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
Academic Journal
S. Tual; C. Lemarchand; M. Boulanger; M. Meryet-Figuière; B. Clin; R. Morello; I. Baldi; P. Lebailly
Revue d'Épidémiologie et de Santé Publique. 71:101773
Academic Journal
Vigneron, Nicolas ; Meryet-Figuière, Matthieu ; Guttin, Audrey ; Issartel, Jean-Paul ; Lambert, Bernard ; Briand, Mélanie ; Louis, Marie-Hélène ; Vernon, Mégane ; Lebailly, Pierre ; Lecluse, Yannick ; Joly, Florence ; Krieger, Sophie ; Lheureux, Stéphanie ; Clarisse, Bénédicte ; Leconte, Alexandra ; Gauduchon, Pascal ; Poulain, Laurent ; Denoyelle, Christophe
In Molecular Oncology August 2016 10(7):981-992
Academic Journal
In Biochimie 2007 89(10):1228-1233
Academic Journal
Denoyelle, C.; Brotin, E.; Duval, R.; Simonin, K.; Meryet-Figuière, M.; N'Diaye, M.; Louis, M.H.; Dutoit, S.; Gauduchon, P.; Poulain, L.
EJC Supplements. 6(9):81-82
Academic Journal
Renier, M.; Hippert, J.; Weiswald, L.-B.; Tual, S.; Meryet-Figuiere, M.; Vigneron, N.; Lebailly, P.; Marcotullio, E.; Baldi, I.
In: Occupational and Environmental Medicine . (Occupational and Environmental Medicine, 10 January 2024, 81(2):75-83)
Academic Journal
Vigneron N; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; Vernon M; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; Meryet-Figuière M; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; Lambert B; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; CNRS, Normandy Delegation, France.; Briand M; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; Louis MH; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; Krieger S; UNICANCER, Cancer Center F. Baclesse, Caen, France.; UNICANCER, Cancer Center F. Baclesse, Biopathology Department, Caen, France.; Normandie Université, UNIROUEN, Inserm U1245, Normandy Center for Genomic and Personalized Medicine, Rouen, France.; Joly F; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; UNICANCER, Cancer Center F. Baclesse, Medical Oncology Department and Clinical Research Unit, Caen, France.; Lheureux S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada.; Blanc-Fournier C; UNICANCER, Cancer Center F. Baclesse, Caen, France.; UNICANCER, Cancer Center F. Baclesse, Biopathology Department, Caen, France.; Gauduchon P; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; Poulain L; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; Denoyelle C; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.
Publisher: Oxford University Press Country of Publication: England NLM ID: 9421549 Publication Model: Print Cited Medium: Internet ISSN: 1530-8561 (Electronic) Linking ISSN: 00099147 NLM ISO Abbreviation: Clin Chem Subsets: MEDLINE
Academic Journal
Busson A; Institut National de la Santé et de la Recherche Médicale (Inserm), Unité Mixte de Recherche (UMR) 1086 ANTICIPE ; Université de Caen Normandie, Esplanade de la Paix, 14000 Caen, France.; Gac AC; Centre Hospitalier Universitaire (CHU) de Caen, Institut d'hématologie de Basse-Normandie, avenue côte de Nacre, 14000 Caen, France.; Gruson B; Centre Hospitalier Universitaire (CHU) d'Amiens-Picardie, Service d'hématologie clinique et de thérapie cellulaire, 30 avenue de la Croix Jourdain, 80054 Amiens Cedex 4, France.; Meryet-Figuière M; Institut National de la Santé et de la Recherche Médicale (Inserm), Unité Mixte de Recherche (UMR) 1086 ANTICIPE, Université de Caen Normandie, Centre Régional de Lutte contre le Cancer François Baclesse, 3 avenue du Général Harris, 14076 Caen Cedex 05, France.; Baldi I; Institut National de la Santé et de la Recherche Médicale (Inserm), Unité (U) 1219 EPICENE, ISPED, Bordeaux Population Health Centre de Recherche, Université de Bordeaux Case 11, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France ; Centre Hospitalier Universitaire (CHU) de Bordeaux, Service de Médecine du Travail et Pathologies Professionnelles, Place Amélie Raba-Léon, 33000 Bordeaux, France.; Tual S; Institut National de la Santé et de la Recherche Médicale (Inserm), Unité Mixte de Recherche (UMR) 1086 ANTICIPE, Université de Caen Normandie, Centre Régional de Lutte contre le Cancer François Baclesse, 3 avenue du Général Harris, 14076 Caen Cedex 05, France.; Lebailly P; Institut National de la Santé et de la Recherche Médicale (Inserm), Unité Mixte de Recherche (UMR) 1086 ANTICIPE, Université de Caen Normandie, Centre Régional de Lutte contre le Cancer François Baclesse, 3 avenue du Général Harris, 14076 Caen Cedex 05, France.
Publisher: EDK Country of Publication: France NLM ID: 8710980 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1958-5381 (Electronic) Linking ISSN: 07670974 NLM ISO Abbreviation: Med Sci (Paris) Subsets: MEDLINE
Academic Journal
Thorel, L.; Morice, P.-M.; Paysant, H.; Florent, R.; Babin, G.; Thomine, C.; Perréard, M.; Abeilard, E.; Giffard, F.; Denoyelle, C.; Briand, M.; Dolivet, E.; Blanc-Fournier, C.; Villedieu, M.; Meryet-Figuiere, M.; Poulain, L.; Weiswald, L.-B.; Brotin, E.; Villenet, C.; Sebda, S.; Figeac, M.; Joly, F.; Goux, D.; Jeanne, C.
In: Journal of Experimental and Clinical Cancer Research . (Journal of Experimental and Clinical Cancer Research, December 2023, 42(1))
Academic Journal
Boulanger, M.; Pons, R.; Bouchart, V.; Lecluse, Y.; Meryet-Figuiere, M.; Tual, S.; Lebailly, P.; De Graaf, L.; Bureau, M.; Baldi, I.
In: Annals of Work Exposures and Health . (Annals of Work Exposures and Health, 1 October 2023, 67(8):965-978)
Academic Journal
Denoyelle, Christophe; Lambert, Bernard; Meryet-Figuière, M; Vigneron, N; Brotin, E; Lecerf, Charlotte; Abeilard, E; Giffard, F; Louis, M-H; Gauduchon, P.; Juin, Phillipe; Poulain, L.
Cell Death Dis
Academic Journal
Meryet-Figuière M; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Lecerf C; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Varin E; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Coll JL; INSERM U1209, Institute of Advanced Biosciences, Institut pour l'Avancée des Biosciences, Centre de Recherche UGA, Site Santé, 38700 La Tronche, France.; Louis MH; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Dutoit S; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Giffard F; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Blanc-Fournier C; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Hedir S; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Vigneron N; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Brotin E; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Pelletier L; INSERM U836, Grenoble Institute of Neurosciences, Bâtiment Edmond J. Safra, Chemin Fortuné Ferrini, Site Santé, 38706 La Tronche Cedex, France.; Josserand V; INSERM U1209, Institute of Advanced Biosciences, Institut pour l'Avancée des Biosciences, Centre de Recherche UGA, Site Santé, 38700 La Tronche, France.; Denoyelle C; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.; Poulain L; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.
Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE
Academic Journal
Renier, M.; Busson, A.; Boulanger, M.; Pons, R.; Tual, S.; Meryet-Figuiere, M.; Clin, B.; Lebailly, P.; Piel, C.; Amadéo, B.; Baldi, I.; Marcotullio, E.
In: International Journal of Cancer . (International Journal of Cancer, 1 June 2022, 150(11):1792-1803)
Academic Journal
Vernon M; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Lambert B; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; CNRS, Normandy Regional Delegation, Caen, France.; Meryet-Figuière M; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Brotin E; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.; Weiswald LB; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Paysant H; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Vigneron N; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Wambecke A; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Abeilard E; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.; Giffard F; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Louis MH; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Blanc-Fournier C; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Biopathology Department, UNICANCER, Cancer Center F. Baclesse, Caen, France.; Gauduchon P; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Poulain L; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.; Denoyelle C; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France. c.denoyelle@baclesse.unicancer.fr.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.
Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Meryet-Figuière, M.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어